Generic LANSOPRAZOLE; NAPROXEN INN entry, pharmaceutical patent and freedom to operate

Sponsor	Phase
Federal University of São Paulo	Phase 4
Fundação de Amparo à Pesquisa do Estado de São Paulo	Phase 4
Takeda	Phase 2

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Na	PREVACID NAPRAPAC 375 (COPACKAGED)	lansoprazole; naproxen	CAPSULE, DELAYED REL PELLETS, TABLET;ORAL	021507-003	Nov 14, 2003		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Takeda Pharms Na	PREVACID NAPRAPAC 500 (COPACKAGED)	lansoprazole; naproxen	CAPSULE, DELAYED REL PELLETS, TABLET;ORAL	021507-004	Nov 14, 2003		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Takeda Pharms Na	PREVACID NAPRAPAC 250 (COPACKAGED)	lansoprazole; naproxen	CAPSULE, DELAYED REL PELLETS, TABLET;ORAL	021507-002	Nov 14, 2003		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 3, 2026

Lansoprazole and naproxen are mature, low-growth generic medicines with limited branded revenue potential. Lansoprazole competes in the proton-pump inhibitor market against omeprazole, esomeprazole, pantoprazole, and rabeprazole. Naproxen competes in the nonsteroidal anti-inflammatory drug market against ibuprofen, diclofenac, celecoxib, and aspirin. Their commercial value is concentrated in low-cost generic and over-the-counter sales, while the lansoprazole-naproxen combination has limited strategic relevance after the decline of branded prescription kits.

The principal business opportunity is not molecule ownership. It is manufacturing efficiency, private-label distribution, consumer branding, modified-release formulation, combination packaging, and channel access.

What are lansoprazole and naproxen used for?

Lansoprazole is a proton-pump inhibitor that suppresses gastric acid secretion. FDA-approved uses include gastroesophageal reflux disease, erosive esophagitis, gastric and duodenal ulcers, and Helicobacter pylori eradication as part of combination therapy (FDA, 2023a).

Naproxen is a nonsteroidal anti-inflammatory drug used for pain and inflammation associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, tendinitis, bursitis, acute gout, and dysmenorrhea. Naproxen sodium is also sold over the counter for temporary relief of minor pain and fever (FDA, 2023b).

The commercial rationale for combining the products is gastrointestinal protection. Naproxen can increase the risk of gastric ulceration and bleeding, while lansoprazole reduces acid-mediated injury. The combination does not eliminate the cardiovascular, renal, bleeding, or other systemic risks associated with naproxen.

What products contain lansoprazole and naproxen?

The relevant products include:

Product or product type	Active ingredient	Market status	Commercial position
Prevacid	Lansoprazole	Mature branded and generic market	Original branded PPI franchise
Generic lansoprazole delayed-release capsules	Lansoprazole	Widely available	Low-price prescription generic
Prevacid 24HR	Lansoprazole	OTC	Consumer self-care product
Naprosyn	Naproxen	Mature branded product	Historical prescription brand
Anaprox	Naproxen sodium	Mature branded product	Historical prescription brand
Generic naproxen and naproxen sodium	Naproxen or naproxen sodium	Widely available	Dominant volume segment
Aleve	Naproxen sodium	OTC	Major consumer brand
Prevacid NapraPAC	Lansoprazole plus naproxen	Legacy prescription kit; limited current commercial relevance	Combination packaging for NSAID users

Prevacid NapraPAC should not be confused with Vimovo. Vimovo contains naproxen and esomeprazole, not naproxen and lansoprazole.

How large is the lansoprazole and naproxen market?

Public companies generally do not report standalone revenue for lansoprazole, naproxen, or the lansoprazole-naproxen combination. Financial analysis therefore depends on prescription volume, OTC retail sales, manufacturer disclosures, and market-share data from commercial databases.

The market has four distinct economic segments:

Prescription generic lansoprazole.
OTC lansoprazole, principally 15 mg delayed-release products.
Prescription generic naproxen and naproxen sodium.
OTC naproxen sodium, principally 220 mg products.

The prescription segments have commodity characteristics. Multiple manufacturers compete on price, supply reliability, wholesaler contracts, and pharmacy purchasing arrangements. OTC products retain greater gross-margin potential because consumer brands, packaging, shelf placement, and advertising support price differentiation.

Naproxen has a broader unit market than the fixed-dose combination because it is used for acute and chronic pain across prescription and OTC channels. Lansoprazole has durable demand because acid-related disorders are common and treatment often recurs, but it faces strong substitution from omeprazole and other PPIs.

What is the financial trajectory for lansoprazole and naproxen?

The financial trajectory is mature-to-declining for branded products and stable-to-low-growth for generic and OTC products.

Period	Lansoprazole trajectory	Naproxen trajectory	Financial interpretation
Pre-generic branded period	High-margin growth	Mature prescription franchise	Brand pricing and physician promotion supported revenue
Generic-entry period	Rapid branded erosion	Continued generic erosion	Volume shifted to lower-cost suppliers
OTC expansion period	Consumer demand supported brand persistence	Aleve and store brands preserved retail value	OTC distribution became more important
Current mature period	Stable demand, low pricing	Stable volume, intense competition	Cash-flow business rather than innovation franchise
Forward outlook	Low-single-digit volume and pricing pressure	Stable-to-low growth with occasional demand spikes	Manufacturing and distribution matter more than patent position

The original Prevacid franchise generated substantial value for its originator, but that value depended on patent protection, branded prescribing, and product-line management. Once generic lansoprazole became available, prescription revenue shifted toward lower-priced suppliers. OTC Prevacid created a separate consumer channel, but it did not restore the economics of a protected prescription product.

Naproxen’s revenue trajectory is older and more commoditized. The underlying molecule has been generic for decades. Current commercial value is concentrated in high-volume, low-cost supply and in OTC brands such as Aleve. No credible investment case depends on renewed exclusivity for naproxen itself.

Which products have the strongest revenue exposure?

The greatest remaining branded exposure is associated with OTC lansoprazole and OTC naproxen sodium. Prescription generic exposure is distributed among manufacturers and wholesalers rather than concentrated in one originator.

The major financial risks are:

Price compression from additional generic suppliers.
Shortages or manufacturing interruptions.
Retailer private-label substitution.
Declining brand loyalty.
PPI substitution by omeprazole and pantoprazole.
NSAID substitution by ibuprofen, acetaminophen, diclofenac, and celecoxib.
Safety-driven prescribing restrictions or reduced chronic NSAID use.

The principal upside is operational. A manufacturer with low-cost delayed-release capsule production, reliable enteric-coating capability, strong OTC distribution, or a differentiated package can earn returns despite weak molecule-level exclusivity.

What patents protect lansoprazole and naproxen?

The core composition patents for both molecules are expired. Current patent value, if any, must come from dosage forms, crystalline forms, manufacturing processes, delivery systems, combinations, or methods of use.

Lansoprazole patent estate

The original lansoprazole compound was protected by early U.S. patents associated with Takeda and its predecessor entities. The core patent estate expired years ago. Generic lansoprazole products are approved principally as delayed-release capsules and other acid-resistant dosage forms.

The most relevant historic protection involved:

The lansoprazole active ingredient.
Enteric-coated or delayed-release formulations.
Granules or pellets designed to protect lansoprazole from gastric acid.
Manufacturing and solid-state characteristics.
Pediatric and therapeutic-use extensions.

The commercial importance of formulation patents was higher than the molecule patent because lansoprazole is acid-labile. A manufacturer must protect the active ingredient until release in the intestine, usually through enteric-coated granules, pellets, or capsules. That technical requirement creates manufacturing complexity, but it does not create durable exclusivity once multiple suppliers have reverse-engineered compliant products.

Naproxen patent estate

Naproxen and naproxen sodium have long-expired composition and basic formulation protection. Current products rely on established tablets, caplets, suspensions, and delayed-release or immediate-release presentations.

Potentially relevant secondary protection can involve:

Naproxen sodium salt selection.
Controlled-release tablets.
Combination products.
Taste masking.
Pediatric liquid formulations.
Packaging and dosing regimens.

These rights generally have limited blocking power because conventional naproxen products are available from numerous manufacturers and alternative dosage forms can be developed without relying on a single branded platform.

When did lansoprazole and naproxen lose exclusivity?

Naproxen lost meaningful U.S. market exclusivity decades ago. It is a mature generic and OTC ingredient.

Lansoprazole’s original compound protection also expired years ago, followed by generic entry and substantial branded prescription erosion. The relevant commercial distinction is between the expired core molecule rights and later formulation, pediatric, or regulatory exclusivities. Those secondary rights did not preserve a durable monopoly over the broader lansoprazole market.

Asset	Exclusivity position	Current implication
Naproxen molecule	Expired	No molecule-level entry barrier
Naproxen sodium	Expired or commercially exhausted	Generic and OTC competition
Lansoprazole molecule	Expired	Broad generic availability
Lansoprazole delayed-release technology	Mature and widely replicated	Technical barrier, not durable market exclusivity
Lansoprazole-naproxen kit	No meaningful broad market exclusivity identified	Limited commercial relevance
OTC brands	Trademark and trade-dress value may remain	Brand investment can support price premium

Exact Orange Book patent status must be evaluated product by product because listed patents can differ by NDA, dosage form, and regulatory status. The economic conclusion is unchanged: neither active ingredient has a commercially meaningful remaining composition-patent moat.

What is the FDA and Orange Book status?

FDA approval exists for multiple prescription and OTC products containing lansoprazole and naproxen. Generic lansoprazole products are generally approved under abbreviated new drug applications, while generic naproxen products are approved under abbreviated pathways or legacy applications depending on product history.

The Orange Book is relevant for listed prescription products, but it does not create protection for the active ingredients themselves. OTC products may be governed by FDA monograph or nonprescription approval pathways and may not present the same Orange Book patent profile as prescription NDAs.

The key regulatory points are:

Lansoprazole delayed-release dosage forms require reliable acid protection and dissolution performance.
Naproxen products require controls for strength, content uniformity, dissolution, and impurity profile.
Fixed-dose combinations require evidence that the components can be co-administered without compromising safety, efficacy, or release characteristics.
OTC labeling must comply with the applicable monograph or approved labeling.
Prescription NSAID labeling includes cardiovascular and gastrointestinal risk warnings (FDA, 2023b).

Are there Paragraph IV challenges for lansoprazole or naproxen?

Paragraph IV litigation was commercially relevant during the original generic-entry process for branded lansoprazole products and other protected PPI formulations. It is not a central current risk for the underlying molecules.

For a new generic entrant, the principal legal exposure would usually concern a specific listed product, formulation, or method-of-use patent rather than the lansoprazole or naproxen molecule. A Paragraph IV certification can trigger litigation under the Hatch-Waxman Act, but the expected value of such litigation is low for ordinary immediate-release naproxen or established delayed-release lansoprazole products with broad generic competition.

What litigation affects lansoprazole and naproxen?

Historic litigation centered on:

Generic entry against branded Prevacid.
PPI formulation and delayed-release patents.
Patent certifications involving branded prescription products.
Combination-drug exclusivity and formulation rights.

Current litigation risk is more likely to arise from manufacturing defects, product liability, labeling, antitrust conduct, supply contracts, or OTC advertising than from a fundamental molecule patent dispute.

What formulation patents protect lansoprazole and naproxen?

Lansoprazole has the more technically important formulation profile. Because it is acid-sensitive, manufacturers need enteric protection and controlled release. The practical barriers include:

Pellet or granule manufacture.
Enteric polymer coating.
Moisture control.
Stability during storage.
Dissolution matching to the reference product.
Capsule filling and scale-up.

Naproxen is easier to manufacture in conventional forms. Its main technical challenges involve tablet compression, dissolution, salt handling, taste, dose uniformity, and, for modified-release products, release control.

A new entrant can usually avoid legacy formulation claims by using a different coating system, manufacturing sequence, excipient combination, or dosage form. Freedom-to-operate analysis remains product-specific, but the broad market does not depend on one formulation patent family.

Which companies are challenging the lansoprazole and naproxen market?

Competition comes from generic manufacturers, OTC brand owners, private-label retailers, contract manufacturers, and vertically integrated distributors. The relevant competitive groups include:

Large generic manufacturers supplying pharmacies and hospitals.
OTC companies selling branded naproxen sodium and lansoprazole.
Retail pharmacy chains selling store-brand equivalents.
Contract development and manufacturing organizations.
Regional suppliers competing during shortages or procurement events.

The competitive advantage varies by segment. Prescription generics compete primarily on cost and supply. OTC products compete on brand recognition, package size, retailer placement, and consumer trust. Combination products compete on convenience, but the market has not supported a large premium over separate generic components.

How does lansoprazole compare with naproxen commercially?

Factor	Lansoprazole	Naproxen
Therapeutic class	Proton-pump inhibitor	NSAID
Main channels	Prescription and OTC	Prescription and OTC
Core patent status	Expired	Expired
Generic intensity	High	Very high
Formulation complexity	Relatively high because of acid instability	Moderate
OTC brand opportunity	Meaningful	Strong
Chronic-use exposure	Common in reflux and ulcer treatment	Common but constrained by safety
Main substitutes	Omeprazole, esomeprazole, pantoprazole	Ibuprofen, diclofenac, celecoxib, acetaminophen
Biosimilar risk	None	None
Main commercial barrier	Enteric-release manufacturing and FDA equivalence	Cost, scale, supply reliability
Revenue outlook	Stable mature demand	Stable mature demand with commodity pricing

Lansoprazole has better formulation complexity and OTC differentiation. Naproxen has broader historical use and stronger OTC recognition but faces more direct commodity competition.

What generic launch scenarios exist?

Conventional generic launch

A manufacturer launches generic delayed-release lansoprazole or generic naproxen under an ANDA. The product competes on price and distribution. This is the lowest-risk regulatory and commercial path but also the least differentiated.

OTC private-label launch

A retailer or consumer-health company markets store-brand lansoprazole or naproxen sodium. The manufacturer earns through supply contracts rather than consumer-facing brand investment. Margins are lower, but volume can be substantial.

Combination packaging

A company packages lansoprazole and naproxen together. This can improve adherence and support a prescription value proposition, but it may face limited demand because physicians and patients can buy inexpensive components separately. Combination packaging also requires regulatory support and clear dosing instructions.

Modified-release or patient-specific formulation

A manufacturer develops a novel release profile, liquid product, sprinkle formulation, or pediatric presentation. This can support a narrower premium, but any patent value depends on enforceable claims and demonstrated clinical or adherence benefits.

Supply-constrained entry

A manufacturer enters during a shortage or after another supplier exits. The opportunity can produce temporary pricing power, but FDA compliance, capacity, and procurement contracts determine whether the gain persists.

What geographic coverage exists?

Lansoprazole and naproxen are sold widely across North America, Europe, Asia-Pacific, and emerging markets. The regulatory and commercial profiles differ:

The United States has a large OTC market and intensive generic competition.
Europe has strong generic penetration and national reimbursement controls.
Japan has established PPI use and a developed branded-generic market.
China and other Asian markets have large volume potential but substantial local competition and price pressure.
Emerging markets favor low-cost tablets, capsules, and private-label products.

Patent barriers are generally weak across major jurisdictions because the core molecules are old. Market access depends more on local registration, manufacturing approval, reimbursement, pharmacy distribution, and tender economics.

What manufacturing and intellectual-property barriers remain?

The principal manufacturing barrier for lansoprazole is high-quality delayed-release production. A supplier must maintain coating uniformity, stability, dissolution performance, and batch consistency. Regulatory observations or supply interruptions can remove a supplier from a market even when patent risk is minimal.

Naproxen manufacturing is less technically differentiated. The key risks are raw-material sourcing, impurity control, scale economics, and compliance with current good manufacturing practices.

Intellectual-property barriers remain most relevant for:

New fixed-dose combinations.
Novel delivery systems.
Pediatric dosage forms.
Controlled-release products.
Branded packaging and trademarks.
Manufacturing processes with narrow claim scope.

How strong is the patent estate for lansoprazole and naproxen?

The patent estate is weak for both molecules and stronger only at the product-specific formulation level.

Category	Lansoprazole	Naproxen
Core molecule protection	1/5	1/5
Formulation complexity	3/5	2/5
Current generic barrier	1/5	1/5
OTC brand value	3/5	4/5
Combination-product opportunity	2/5	2/5
Long-term pricing power	1/5	1/5

These scores reflect commercial defensibility rather than a legal opinion on any particular patent claim.

Key Takeaways

Lansoprazole and naproxen are mature, largely commoditized pharmaceutical ingredients.
Both core molecule patent estates are expired and do not support meaningful current exclusivity.
Lansoprazole has greater formulation complexity because delayed-release protection is required.
Naproxen has broader OTC penetration but more intense commodity competition.
The lansoprazole-naproxen combination has limited commercial differentiation because separate generic products are inexpensive.
Biosimilar risk is irrelevant because both products are small-molecule drugs.
Current revenue potential is concentrated in OTC brands, private-label supply, manufacturing scale, and distribution.
Generic entry risk is high, while current Paragraph IV risk is generally product-specific rather than molecule-wide.
Long-term financial growth is unlikely without a differentiated formulation, strong consumer brand, or supply-chain advantage.

FAQs

Is lansoprazole still a profitable drug?

It can be profitable as a generic or OTC product, but profitability depends on manufacturing cost, supply reliability, retailer access, and brand positioning rather than patent exclusivity.

Is naproxen more commercially valuable than lansoprazole?

Naproxen generally has broader consumer recognition and OTC volume. Lansoprazole can support higher formulation and brand differentiation because of its delayed-release requirements.

Is Prevacid NapraPAC still a major commercial product?

No. The combination has limited current importance compared with separate generic lansoprazole and naproxen products and competing products such as naproxen-esomeprazole.

Can a company patent a new lansoprazole-naproxen product?

Potentially, but protection would need to rely on a novel formulation, release profile, manufacturing process, dosage regimen, or clinically meaningful combination claim. The old combination concept alone is unlikely to provide broad exclusivity.

What is the greatest investment risk in these products?

The greatest risk is sustained price erosion from generic and private-label competition. For lansoprazole, manufacturing defects involving delayed release are a material operational risk. For naproxen, safety concerns and substitution by other analgesics constrain chronic-use growth.

References

U.S. Food and Drug Administration. (2023a). Prevacid (lansoprazole) prescribing information. FDA.
U.S. Food and Drug Administration. (2023b). Naproxen and naproxen sodium prescribing and over-the-counter labeling information. FDA.
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs database. FDA.
U.S. Food and Drug Administration. (1984). Hatch-Waxman Amendments and abbreviated new drug application framework. FDA.
Takeda Pharmaceutical Company Limited. (2009). Annual report and securities report. Takeda Pharmaceutical Company Limited.

US Patents:	0
Tradenames:	3
Applicants:	1
NDAs:	1
Clinical Trials:	4
DailyMed Link:	LANSOPRAZOLE; NAPROXEN at DailyMed

LANSOPRAZOLE; NAPROXEN - Generic Drug Details

What are the generic drug sources for lansoprazole; naproxen and what is the scope of patent protection?

Summary for LANSOPRAZOLE; NAPROXEN

Recent Clinical Trials for LANSOPRAZOLE; NAPROXEN

Anatomical Therapeutic Chemical (ATC) Classes for LANSOPRAZOLE; NAPROXEN

US Patents and Regulatory Information for LANSOPRAZOLE; NAPROXEN

Lansoprazole and Naproxen Market Dynamics, Patent Expiration, Litigation Risk, and Financial Trajectory